Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
July 27, 2026
Novedosos productos celulares pueden mejorar los desenlaces clínicos del trasplante de sangre de cordón umbilical
Del Dr. Filippo Milano y sus colegas, Departamento de Ciencias Traslacionales y Terapéuticas
New cell products can improve cord blood transplant outcomes
From Dr. Filippo Milano and colleagues, Translational Sciences and Therapeutics Division
Umbilical cord blood transplant with pooled stem cell product shows 96% survival and no graft-versus-host-disease in leukemia patients
A phase 2 study published in the Journal of Clinical Oncology shows that a stem cell product called dilanubicel safely enabled umbilical cord blood transplants in 28 patients
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger”
Testing cord blood transplants as a cure for leukemia — and HIV
New clinical trial at several U.S. cancer centers will enroll people living with HIV and advanced leukemia
T cell diversity as a measure of immune recovery following CBT
From the Cord Blood Group and colleagues, Clinical Research Division
Study aims to cure blood cancers with transplants that could block HIV, too
10 HIV-positive cancer patients to receive donated cord blood with rare resistance gene
Good News: Kleberg Foundation grant to support clinical trial for leukemia patients
Celebrating faculty and staff achievements
Umbilical cord blood transplant linked to lower relapse in high-risk leukemia patients
Study compares ‘alternative’ donor source vs. traditional transplantation of blood stem cells from an adult, unrelated donor